Vilaprisan
Clinical data | |
---|---|
Other names | BAY-1002670; 17β-Hydroxy-11β-[4-(methylsulfonyl)phenyl]-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one |
Routes of administration | By mouth |
Drug class | Selective progesterone receptor modulator |
Identifiers | |
| |
JSmol) | |
| |
|
Vilaprisan (
uterine fibroids.[1][2][3] It is a potent and highly selective partial agonist of the progesterone receptor (PR).[4][2][3] As of 2017, the drug is in phase II clinical trials for the aforementioned indications.[1]
See also
- List of investigational sex-hormonal agents § Progestogenics
- Lonaprisan
- Mifepristone
- Onapristone
- Ulipristal acetate
References
External links